Search

Your search keyword '"Balmaña, J"' showing total 499 results

Search Constraints

Start Over You searched for: Author "Balmaña, J" Remove constraint Author: "Balmaña, J"
499 results on '"Balmaña, J"'

Search Results

2. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

5. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

7. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

11. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

12. 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial

13. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

14. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

15. Risk factors of complications after nipple-sparing mastectomies in women with breast cancer risk gene mutations (BRCA1, BRCA2, PALB2)

16. 146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)

17. EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)

18. 262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis

27. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

28. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

29. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

30. 139P Breast cancer risk estimation (CanRisk tool) and perception in unaffected women with family history of breast cancer

31. 12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients

33. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

39. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

40. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe

41. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.

44. 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial

45. 1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests

46. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

47. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

48. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

49. Reply to Kratz et al.

50. Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes

Catalog

Books, media, physical & digital resources